FoundationOne Liquid
Foundation Medicine receives FDA approval for pan-tumour biopsy test
FDA Approves FoundationOne Liquid CDx for Advanced Cancer
Introducing our next-generation liquid biopsy
Testing for MET Exon 14 Skipping | TABRECTA® (capmatinib) tablets
FoundationOne Liquid CDx
FoundationOne Liquid CDx
FoundationOne Liquid
FoundationOne Liquid CDx
FoundationOne®Liquid CDx Companion Diagnostic Approved in NSCLC, Advanced Ovarian and Breast Cancer - Onco'Zine
Sep 09, 2021| Information meeting on FoundationOne CDx Cancer Genomic Profile
Liquid Biopsy to Identify Actionable Genomic Alterations | American Society of Clinical Oncology Educational Book
FoundationOne Liquid CDx
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
FoundationOne Liquid CDx
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges | British Journal of Cancer
Multi-gene Testing (NGS) for PIK3CA Mutations
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin | PLOS ONE
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
Multi-gene Testing (NGS) for PIK3CA Mutations
FoundationOne Liquid CDx assay utilization overview. FoundationOne... | Download Scientific Diagram
Foundation Medicine Heme Brochure for Patients with Blood cancers and Sarcomas
JCI Insight - Multiparametric liquid biopsy analysis in metastatic prostate cancer
Latest Medical News
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Business Wire
